Drug giants eye China for deals despite growing Sino-US tensions | Reuters
Excerpt from Reuters: “Some of the biggest global drugmakers, undeterred by mounting Sino-U.S. tensions, are scouring for deals in China to replenish drug pipelines and boost their presence in the world’s second-biggest pharmaceutical market, industry executives and investment bankers said…” Read more.
Adial Pharmaceuticals moves forward to second cohort in pharmacokinetics study of AD04 for alcohol use disorder | Yahoo Finance
Excerpt from Yahoo Finance: “On Tuesday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced the progression to the second cohort in the pharmacokinetics study of AD04. AD04 is the company’s lead investigational genetically targeted serotonin-3 receptor antagonist, a therapeutic agent for Alcohol Use Disorder (AUD) in heavy drinking patients, following the completion of the first cohort…” Read more.
Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules | The Guardian
Excerpt from The Guardian: “An obscure federal statute is allowing US pharmacies to flood the market with unvetted knockoffs of Ozempic, the pricey weight-loss drug that is reducing and transforming the weight and silhouettes of millions of Americans…” Read more.
Sorry, the comment form is closed at this time.